Uri Weinberg Biography and Net Worth

Insider of NovoCure

Dr. Uri Weinberg currently serves as Novocure’s Chief Science Officer overseeing early-stage research and development as well as the design and development stages of all clinical trials. Since joining Novocure in 2008, he has held several positions throughout his tenure with the company. Dr. Weinberg managed Novocure’s first clinical trial in lung cancer as well as the EF-14 clinical trial in newly diagnosed glioblastoma and built the company’s global Clinical Operations team in Switzerland. Prior to becoming Chief Science Officer in March 2020, Dr. Weinberg most recently held the position of Vice President of Clinical Development where he was responsible for expanding research activities, strengthening global clinical collaboration and initiating new discovery programs. Dr. Weinberg holds an M.D. Ph.D. from the Technion – Israel Institute of Technology.

What is Uri Weinberg's net worth?: The estimated net worth of Uri Weinberg is at least $538,044.98 as of January 5th, 2023. Dr. Weinberg owns 43,286 shares of NovoCure stock worth more than $538,045 as of April 26th. This net worth evaluation does not reflect any other assets that Dr. Weinberg may own. Learn More about Uri Weinberg's net worth.
How do I contact Uri Weinberg?: The corporate mailing address for Dr. Weinberg and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Uri Weinberg's contact information.
Has Uri Weinberg been buying or selling shares of NovoCure?: Uri Weinberg has not been actively trading shares of NovoCure within the last three months. Most recently, Uri Weinberg sold 8,143 shares of the business's stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $116.14, for a transaction totalling $945,728.02. Following the completion of the sale, the insider now directly owns 43,286 shares of the company's stock, valued at $5,027,236.04. Learn More on Uri Weinberg's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 9 times. They sold a total of 9,753 shares worth more than $163,632.37. The most recent insider tranaction occured on March, 4th when EVP Frank X Leonard sold 840 shares worth more than $13,448.40. Insiders at NovoCure own 5.7% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 3/4/2024.

Uri Weinberg Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/5/2023	Sell	8,143	$116.14	$945,728.02	43,286
9/25/2020	Sell	15,250	$103.35	$1,576,087.50	36,347

Uri Weinberg Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $12.64

$12.01

$12.65

50 Day Range

MA: $14.42

$11.83

$17.29

2 Week Range

Now: $12.64

$10.87

$83.60

Volume

761,583 shs

Average Volume

1,337,344 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>